EICHORCondition: Pulmonary Mycobacterium Avium Complex Infection · Bronchiectasis · Lung Diseases · Sponsor: RedHill Biopharma Limited
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung infection.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Medical Facility | Glendale, California, United States | — |
| Medical Facility | Palm Springs, California, United States | — |
| Medical Facility | Farmington, Connecticut, United States | — |
| Medical Facility | Washington D.C., District of Columbia, United States | — |
| Medical Facility | Clearwater, Florida, United States | — |
| Medical Facility | Gainesville, Florida, United States | — |
| Medical Facility | Margate, Florida, United States | — |
| Medical Facility 1 | Orlando, Florida, United States | — |
| Medical Facility 2 | Orlando, Florida, United States | — |
| Medical Facility | Sebring, Florida, United States | — |
| Medical Facility | Vero Beach, Florida, United States | — |
| Medical Facility | Atlanta, Georgia, United States | — |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04616924